Zydus Cadila gets USFDA’s final nod for fungal treatment drug

Drug firm ZydusCadila has received final approval from the US health regulator to market Voriconazole tablets, used to treat fungal infections, in the American market.The ZydusCadila has received final approval from the US Food and Drug Administration (USFDA) to market Voriconazole tablets in strengths of 50 and 200 mg, CadilaHealhtcare said in a BSE filing.

The drug will be produced at the groups formulations manufacturing facility at Baddi (Himachal Pradesh).

Citing IMS data, the company said the estimated sales for Voriconazole tablets is USD 92.8 million as on March 2016.

Related Posts

NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

The officials identified the substance as Alprazolam manufactured illegally at the lab. HYDERABAD: In one of the largest such seizures in recent times, the Narcotics Control Bureau (NCB), Hyderabad, raided…

Govt Outlines AYUSH Heavy Metal Monitoring Steps In Rajya Sabha

New Delhi: The Ministry of AYUSH has detailed its regulatory framework and ongoing initiatives to monitor heavy metal content in traditional medicines, responding to parliamentary concerns over quality and safety…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

ED attaches assets, freezes bank account in counterfeit medicines racket; searches five premises in Bengaluru

ED attaches assets, freezes bank account in counterfeit medicines racket; searches five premises in Bengaluru

Hyderabad Startup Working On Personalised Cancer Vaccine: What It Means For Cancer Treatment

Hyderabad Startup Working On Personalised Cancer Vaccine: What It Means For Cancer Treatment

Medicines that cure Us are making Our Environment Sick

Medicines that cure Us are making Our Environment Sick

ZEN- G packs a punch in Organ Donation as Over 500 Students pledge Organs

ZEN- G packs a punch in Organ Donation as Over 500 Students pledge Organs

PGIMS recalls drug amid probe into deaths

PGIMS recalls drug amid probe into deaths

NPPA list brings little relief: No price cut for 25% cancer drugs

NPPA list brings little relief: No price cut for 25% cancer drugs